Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 3/20 | 0.58 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.52 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.52 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.52 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.51 |
| ▸ | AMY2A | P04746 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 6/20 | 0.48 |
| ▸ | FGF1 | P05230 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15215700 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL7743926 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL13125623 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL15216253 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL20658640 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL23475838 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL7871307 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL18821917 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL12070983 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A | |
| SCHEMBL14421628 | 1.00 | LGALS8 (0.58) | LGALS8LGALS3LGALS4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7947733-B2 | Phosphorylated pyrone analogs and methods | LIMERICK BIOPHARMA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110028437-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | LIMERICK BIOPHARMA, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | LIMERICK BIOPHARMA, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | LIMERICK BIOPHARMA, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090088394-A1 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | ROBBINS WENDYE | 2009-04-02 | — | — | US | disclosed |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | LIMERICK BIOPHARMA, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20070087977-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | LIMERICK BIOPHARMA, INC. | 2007-04-19 | — | — | US | disclosed |
| US-6562514-B1 | Stabilized vanadium electrolyte solutions for all-vanadium redox cells and batteries | PINNACLE VRB LIMITED (AU) | 2003-05-13 | — | — | US | disclosed |
| US-6468688-B2 | CHARGING, DISCHARGING EFFICIENCY; VANADIUM ELECTROLYTE | PINNACLE VRB LIMITED (AU) | 2002-10-22 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | LGALS8 402/4885LGALS3 1672/4885LGALS4 1475/4885 |
| US-20090325906-A1 | Methods and compositions for therapeutic treatment | SLC2A1, SLC2A2, SLC2A3 | LGALS8 950/4885LGALS3 915/4885LGALS4 1025/4885 |
| US-20070087977-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | PGF, FABP7, ALPP | LGALS8 1381/4885LGALS3 618/4885LGALS4 1331/4885 |
| US-20090088394-A1 | METHODS AND COMPOSITIONS FOR THERAPEUTIC TREATMENT | PGF, FABP7, ALPP | LGALS8 840/4885LGALS3 374/4885LGALS4 783/4885 |
| US-20100297020-A1 | PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT | PC, PCK1, PYGL | LGALS8 1894/4885LGALS3 3161/4885LGALS4 3317/4885 |
| US-20100189653-A1 | Pyrone analogs for therapeutic treatment | PC, GLS2, CYP27A1 | LGALS8 895/4885LGALS3 1844/4885LGALS4 1824/4885 |
| US-20110028437-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | LGALS8 1717/4885LGALS3 3021/4885LGALS4 3622/4885 |
| US-20100204089-A1 | PHOSPHORYLATED PYRONE ANALOGS AND METHODS | PCK1, PC, PCK2 | LGALS8 1717/4885LGALS3 3021/4885LGALS4 3622/4885 |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | LGALS8 402/4885LGALS3 1672/4885LGALS4 1475/4885 |
| US-20090082400-A1 | SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS | PGF, ABCG2, PYGB | LGALS8 489/4885LGALS3 736/4885LGALS4 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.